Buy Sermorelin – Peptide Partners

Product Overview & Specifications

Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analog investigated for its role in GH secretion modulation, cell proliferation effects, and metabolic stability in preclinical research. Peptide Partners supplies this research-grade material for in-vitro testing, laboratory experimentation, receptor pharmacology, structural biology, and analytical method development.

Published studies have examined sermorelin using glioma cell lines (U87, LN229), in vitro urine metabolism assays, human plasma incubation studies, LC-HRMS/MS detection methods, immunoaffinity purification techniques, and anti-doping analytical protocols. Research areas include GHRH receptor binding, cell cycle modulation, metabolite identification, DPP-IV enzymatic degradation, and analytical detection methodology.

The product name supplied for this listing is “Sermorelin.” Researchers should verify the exact identity, sequence, formulation, and batch-specific certificate of analysis before beginning any experiment. Findings from published sermorelin studies should not be assumed to apply to every commercial batch or formulation.

Product Specifications

Specification	Details
Product name	Sermorelin
Compound type	Synthetic growth hormone-releasing hormone (GHRH) analog
Primary molecular targets	GHRH receptors, dipeptidyl peptidase-IV (DPP-IV) enzyme
Primary research areas	GH secretion modulation, cell proliferation studies, metabolite characterization, analytical detection methods, anti-doping analysis, and glioma cell biology
Product format	10 mg vials
Vial size	10 mg
Vial capacity	3 mL
Available box combinations	20 mg, 50 mg, 100 mg, and 200 mg
Multi-vial purity	99.94%
Independent testing	Yes
Endotoxin screening	Passed
Heavy-metals screening	Passed
Purity screening	Passed
Manufacturer ID	VI32
Batch ID	SER202601
Cost per milligram	$3.98–$4.90

The stated 99.94% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

A Potentially Effective Drug for Patients with Recurrent Glioma: Sermorelin

Authors: Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, and Hu H

Publication: Frontiers in Oncology, 2021

PMCID: PMC8033379

Reference: View publication

The study investigated the effect of sermorelin on glioma cell lines U87 and LN229. The results showed that sermorelin inhibited the proliferation of these cells in a dose-dependent manner. The study suggests that sermorelin may inhibit tumor cell proliferation by blocking the cell cycle.

Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses found that the Drug Resistance Score (DRS) of sermorelin was negatively correlated with cell proliferation and immune function. The researchers employed computational biology approaches alongside cell culture experiments to characterize sermorelin’s effects on glioma cell behavior.

The findings indicate that sermorelin exhibits anti-proliferative activity in glioma cell lines through cell cycle interference mechanisms. The study provides a foundation for further investigation of sermorelin’s effects on cancer cell biology in laboratory research settings.

Plain-English Research Summary

This research explored whether the peptide Sermorelin could be a potential treatment for a type of brain tumor called glioma. The scientists tested Sermorelin on cancer cells in a lab dish and found that it could stop the cancer cells from growing. The study suggests that Sermorelin might work by interfering with the cancer cells’ ability to divide and multiply. It also seems to boost the immune system’s ability to fight the cancer. This is an early-stage study, but it suggests that Sermorelin could be a promising new drug for patients with recurrent glioma.

Advances in the Detection of Growth Hormone Releasing Hormone Synthetic Analogs

Authors: Memdouh S, Gavrilović I, Ng K, Cowan D, and Abbate V

Publication: Drug Testing and Analysis (Wiley), 2022

DOI: 10.1002/dta.3183

Reference: View publication

This study investigates the in vitro metabolism of four growth hormone-releasing hormone (GHRH) synthetic analogs, including sermorelin, in fortified urine for anti-doping purposes. The researchers identified nineteen major in vitro metabolites of these GHRH analogs. For sermorelin, several degradation products were identified, which will aid in the development of more effective detection methods for its misuse in sports.

The research employed advanced analytical chemistry techniques to characterize metabolite profiles of GHRH analogs in biological matrices. The metabolite identification data supports the development of sensitive, specific detection methods for anti-doping laboratories and forensic applications.

The findings provide a comprehensive metabolite profile for sermorelin and related GHRH analogs, enabling more accurate detection in biological samples. This research is critical for maintaining the integrity of competitive sports and ensuring fair play through reliable analytical testing protocols.

Plain-English Research Summary

Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in urine. In the lab, they mixed Sermorelin with urine and observed how it breaks down. They identified several smaller pieces, or ‘metabolites’. Knowing what these metabolites look like is crucial for creating a reliable drug test, because the test can then look for these specific markers.

Qualitative Identification of Growth Hormone-Releasing Hormones in Human Plasma by Means of Immunoaffinity Purification and LC-HRMS/MS

Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, and Thevis M

Publication: Drug Testing and Analysis, 2016

PMCID: PMC4830873

Reference: View publication

This study aimed to develop a method for detecting various growth hormone-releasing hormones (GHRHs), including Sermorelin, in human plasma for anti-doping purposes. In an in-vitro experiment, Sermorelin was incubated in human plasma. The researchers observed that Sermorelin was completely degraded after 4 hours. They identified a metabolite, GRF(3-29), which results from the cleavage of the N-terminal Tyr-Ala-residue by the enzyme dipeptidyl peptidase-IV (DPP-IV).

This finding is important for developing effective anti-doping tests, as it’s often the metabolites of a substance, rather than the substance itself, that are detected in biological samples. The study utilized immunoaffinity purification coupled with liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) for sensitive and specific detection.

The research demonstrates that sermorelin undergoes rapid enzymatic degradation in plasma through DPP-IV-mediated cleavage, producing characteristic metabolites that serve as detection markers. The analytical methodology developed in this study provides a robust framework for GHRH analog detection in forensic and anti-doping laboratories.

Plain-English Research Summary

Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in blood. In the lab, they mixed Sermorelin with human blood plasma and observed how it breaks down. They found that Sermorelin is broken down into a smaller piece, a ‘metabolite’. Knowing what this metabolite looks like is crucial for creating a reliable drug test, because the test can then look for this specific marker.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, growth hormone treatment, performance-enhancing compound, anti-aging product, cancer treatment, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.